Phibro Animal Health Corporation Class A (PAHC)

Over the past six months, Phibro Animal Health Corp. stock has experienced several notable events, including a significant gain of 210.0% over the past 12 months. Phibro reported its first-quarter fiscal year 2026 results, with net sales up 40% and adjusted diluted EPS doubling. The company announced a leadership transition. Phibro Animal Health Corporation declared a quarterly dividend. Phibro reported its second-quarter fiscal year 2026 results, exceeding expectations with significant year-over-year growth in sales and profitability, and updated its financial guidance, leading to a +21.95% increase in stock price on February 4, 2026. Phibro Animal Health Corporation participated in the Bank of America 2026 Virtual Animal Health Summit. BFI Co. LLC sold 14,080 shares. FMR LLC reported a 10.5% stake in PAHC.

Demand for Phibro Animal Health Corp.'s products and services, particularly within its Animal Health segment, is subject to seasonality due to changing disease pressures and varying weather conditions. This can lead to regional and seasonal fluctuations in demand. However, "Seasonal Demand Strength" driven by the healthy protein industry is also identified as a short-term catalyst for the company. The company's business is currently concentrated in the livestock sector, but it is investing resources to develop products for the companion animal sector.

Phibro Animal Health Corp. operates in the animal health and nutrition industry, developing, manufacturing, and marketing products for food animals and companion animals. The company's business is structured into three main segments: Animal Health, Mineral Nutrition, and Performance Products. Major products in the Animal Health segment include antibacterials, anticoccidials, nutritional specialty products, and vaccines. The Mineral Nutrition segment focuses on formulations and concentrations of trace minerals. The Performance Products segment manufactures and markets specialty ingredients for use in various industries.

Phibro Animal Health Corp. has a significant global presence, marketing products in over 90 to 95 countries to around 4,000 to 4,500 customers. The company's operations span North America, Latin America, Asia Pacific, Europe, Africa, and the Middle East. It maintains offices across the United States and globally.

Phibro Animal Health Corp.'s brand reputation in the past year has been positively influenced by strategic growth initiatives and product innovation. Phibro acquired Zoetis Inc.'s medicated feed additive portfolio and water-soluble products for $350 million, expanding Phibro's global presence and product offerings. The national launch of Restoris™ piezoelectric dental gel for dogs with periodontal disease demonstrates the company's investment in the companion animal sector and innovation. The "Phibro Forward" initiative contributes to a perception of a well-managed and forward-thinking company.

The ownership structure of Phibro Animal Health Corp. is a mix of institutional, retail, and individual investors. The Bendheim family, through BFI Co., LLC, holds a dominant position in the company's voting power. Jack C. Bendheim is the largest individual shareholder with 53.22% ownership. Major institutional investors include BlackRock, Inc., Vanguard Group Inc., and State Street Corp. As of April 2, 2026, 225 institutional owners and shareholders held a total of 19,025,383 shares. Insiders own approximately 1.04% of the company's stock, while institutional investors hold about 62.44% and public companies and individual investors hold approximately 36.51%.